Friday, November 22, 2024
Home Business Sun Pharma completes Taro merger in a deal valued at $348 million

Sun Pharma completes Taro merger in a deal valued at $348 million

by
0 comment

Sun Pharma

announced the successful completion of the

merger

of its

US subsidiary

,

Taro Pharmaceutical

with itself, in a deal valued at nearly $348 million. Last month, Taro announced that its shareholders had approved the merger agreement with Sun Pharma.
As a result of the merger, Taro will be delisted from the NYSE and become a privately-held company, wholly-owned by Sun Pharma.
Sun Pharma has been the majority shareholder of Taro since 2010.
The company had first announced to take over the US generics major 17 years ago, in 2007, for $454 million, but the Taro shareholders had rejected the takeover.

As part of this merger concluded on June 24, Sun Pharma acquired all outstanding ordinary shares of Taro other than the shares already held by Sun Pharma or its affiliates, a company statement said.
In May last year, Sun Pharma had issued a letter to the Taro board with a proposal containing a non-binding indication of interest to acquire all the outstanding ordinary shares in Taro, for a purchase price of $38 per share.
After negotiations, the deal was sweetened in December last year, with the purchase price revised to $43 per share.

You may also like

Leave a Comment

About Us

Welcome to Janashakti.News, your trusted source for breaking news, insightful analysis, and captivating stories from around the globe. Whether you’re seeking updates on politics, technology, sports, entertainment, or beyond, we deliver timely and reliable coverage to keep you informed and engaged.

@2024 – All Right Reserved – Janashakti.news